|
1
|
Kaufmann SH: Is the development of a new
tuberculosis vaccine possible? Nat Med. 6:955–960. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fuller DH, Rajakumar PA, Wilson LA, et al:
Introduction of mucosal protection against primary, heterologous
simian immunodeficiency virus by a DNA vaccine. J Virol.
76:3309–3317. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Havlir DV, Wallis RS, Boom WH, Daniel TM,
Chervenak K and Ellner JJ: Human immune response to
Mycobacterium tuberculosis antigens. Infect Immun.
59:665–670. 1991.
|
|
4
|
Weldingh K, Rosenkrands I, Jacobsen S,
Rasmussen PB, Elhay MJ and Andersen P: Two-dimensional
electrophoresis for analysis of Mycobacterium tuberculosis
culture filtrate and purification and characterization of six novel
proteins. Infect Immun. 66:3492–3500. 1998.PubMed/NCBI
|
|
5
|
Malin AS, Huygen K, Content J, et al:
Vaccinia expression of Mycobacterium tuberculosis-secreted
proteins: tissue plasminogen activator signal sequence enhances
expression and immunogenicity of M. tuberculosis Ag85.
Microbes Infect. 2:1677–1685. 2000.
|
|
6
|
Romano M, Roupie V, Wang XM, et al:
Immunogenicity and protective efficacy of tuberculosis DNA vaccines
combining mycolyl-transferase Ag85A and phosphate transport
receptor PstS-3. Immunology. 118:321–332. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Oettinger T, Holm A and Hasløv K:
Characterization of the delayed type hypersensitivity-inducing
epitope of MPT64 from Mycobacterium tuberculosis. Scand J
Immunol. 45:499–503. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kamath AT, Feng CG, Macdonald M, Briscoe H
and Britton WJ: Differential protective efficacy of DNA vaccines
expressing secreted proteins of Mycobacterium tuberculosis.
Infect Immun. 67:1702–1707. 1999.PubMed/NCBI
|
|
9
|
Tehranchian S, Akbarzadeh T, Fazeli MR,
Jamalifar H and Shafiee A: Synthesis and antibacterial activity of
1-[1,2,4-triazol-3-yl] and
1-[1,3,4-thiadiazol-2-yl]-3-methylthio-6,7-dihydrobenzo[c]thiophen-4(5h)ones.
Bioorg Med Chem Lett. 15:1023–1025. 2005.
|
|
10
|
Wang Z, Potter BM, Gray AM, Sacksteder KA,
Geisbrecht BV and Laity JH: The solution structure of antigen MPT64
from Mycobacterium tuberculosis defines a new family of
beta-grasp proteins. J Mol Biol. 366:375–381. 2007.PubMed/NCBI
|
|
11
|
Bastos RG, Ueti MW, Knowles DP and Scoles
GA: The Rhipicephalus (Boophilus) microplus Bm86 gene plays a
critical role in the fitness of ticks fed on cattle during acute
Babesia bovis infection. Parasit Vectors. 3:1112010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Choi SS, Chung E and Jung YJ: Newly
identified CpG ODNS, M5-30 and M6-395, stimulate mouse immune cells
to secrete TNF-alpha and enhance Th1-mediated immunity. J
Microbiol. 48:512–517. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
de Klerk LM, Michel AL, Bengis RG, Kriek
NP and Godfroid J: BCG vaccination failed to protect yearling
African buffaloes (Syncerus caffer) against experimental
intratonsilar challenge with Mycobacterium bovis. Vet
Immunol Immunopathol. 137:84–92. 2010.PubMed/NCBI
|
|
14
|
Liang Y, Wu X, Zhang J, et al: The
treatment of mice infected with multi-drug-resistant
Mycobacterium tuberculosis using DNA vaccines or in
combination with rifampin. Vaccine. 26:4536–4540. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ingolotti M, Kawalekar O, Shedlock DJ,
Muthumani K and Weiner DB: DNA vaccines for targeting bacterial
infections. Expert Rev Vaccines. 9:747–763. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cai H, Tian X, Hu XD, Zhuang YH and Zhu
YX: Combined DNA vaccines formulated in DDA enhance protective
immunity against tuberculosis. DNA Cell Biol. 23:450–456. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Takeno M, Murakami S and Ishigatsubo Y:
Tuberculosis associated with anti-TNF therapy. Nippon Rinsho.
65:1308–1313. 2007.(In Japanese).
|
